Alzheimer's Disease is a devastating neurological disorder characterized by Amyloid- β peptide aggregations in the brain. These aggregations have high concentrations of metal ions that may be possible therapeutic targets. My research takes advantage of the metal-binding affinity of Aβ peptides and tests ruthenium metal complexes for their prospective ability to limit peptide aggregations and cytotoxicity. Using glial cells as a model system, I investigate the potency of the ruthenium metal complexes against peptide plaques and assess their safety in the brain. This research may eventually be useful for the development of treatments for Alzheimer’s Disease.